These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
3 files

A Technoeconomic Evaluation of the Potential of Industrial Biotechnology for the Competitive Production of Commodity and Bulk Chemicals

submitted on 15.11.2020, 16:37 and posted on 16.11.2020, 12:45 by Jennifer Hennigan, Phillip Wagner, Chris Burk, John Efromson, Zhixia Ye, Matthew Lipscomb, Michael Lynch

Fermentation based bioprocesses are routinely developed for higher value products; however, the development of bioprocesses for larger volume chemicals has lagged. While electrification of transportation may enable significant reductions in greenhouse gas emissions in the fuel sector, the production of chemicals, by its very nature, requires a carbon feedstock. The utilization of more sustainable bioprocessing has unique potential in this sector. Despite the start- up of several bio-based chemical facilities none of these technologies have had break-out success, as measured by the construction of multiple follow on plants. A key barrier to the wide-spread adoption of large scale bio-based processes includes the potential financial return on capital spent on new facilities and, importantly, the comparative financial return for bioprocesses vs. incumbent petrochemical technology. A standard metric of a project’s financial return is the internal rate of return or IRR. Bio-based chemical processes will likely not be extensively commercialized unless they have an IRR that is competitive with petrochemical routes.


DARPA # HR0011-14-C- 0075

ONR YIP # 12043956

DOE EERE #EE0007563

NIH # T32GM008555.


Email Address of Submitting Author


Duke University


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

P.S. Wagner, Z. Ye, M.L. Lipscomb, and M.D. Lynch have a financial interest in DMC Biotechnologies, Inc. J.N. Hennigan and M.D. Lynch have a financial interest in Roke Biotechnologies, LLC.. C. Burk has a financial interest in Burk TechnoEconomics.